Patents by Inventor Dirk Block

Dirk Block has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11047866
    Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 29, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20210164969
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Heudig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 10996229
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 4, 2021
    Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of Toronto
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10942175
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 9, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Huedig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20200371114
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: December 19, 2019
    Publication date: November 26, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20200271670
    Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 27, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
  • Patent number: 10684291
    Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
  • Publication number: 20200064359
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 27, 2020
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10557858
    Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 11, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10488422
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: November 26, 2019
    Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of Toronto
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Publication number: 20190353666
    Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Dirk Block, Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Roberto Latini, Serge Masson, Andre Ziegler, Edelgard Kaiser, Stefan Palme, Markus Thomas, Simona Barlera
  • Publication number: 20190279770
    Abstract: The present disclosure relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), using the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: October 12, 2018
    Publication date: September 12, 2019
    Applicants: Roche Diagnostics Operations, Inc., Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu
    Inventors: Dirk Block, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler, Faiez Zannad, Patrick Rossignol
  • Publication number: 20190277861
    Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Patent number: 10345315
    Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 9, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20190154706
    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 23, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Patent number: 10234462
    Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10234464
    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Publication number: 20180364248
    Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
    Type: Application
    Filed: August 23, 2018
    Publication date: December 20, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Martin Hund, Edelgard Anna Kaiser, Ursula-Henrike Wienhues-Thelen, Dirk Block, Johann Karl
  • Publication number: 20180313850
    Abstract: The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Julian Braz, Hans-Peter Brunner, James Creeden, Hans-Joerg Loyda, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
  • Publication number: 20180231570
    Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 16, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Andrea Horsch, Birgit Klapperich, Dirk Block, Alfred Engel, Johann Karl, Rosemarie Kientsch-Engel, Ekaterina Manuilova, Christina Rabe, Sandra Rutz, Monika Soukupova, Ursula-Henrike Wienhues-Thelen, Peter Kastner, Edelgard Anna Kaiser